EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The feasibility and specific aspects of hematopoietic stem cell transplantation in children with pre-transplant invasive mucormycosis

Galina G. Solopova, L. N. Shelikhova, Zh. V. Markova, A. P. Shcherbakov, A. D. Voropaev, N. V. Suvorova, A. A. Maschan, G. A. Novichkova

Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 96-106

DOI: 10.24287/j.1123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Galina G. Solopova und 7 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The rising incidence of mucormycosis among patients with hematologic and oncologic conditions has made it crucial to develop principles for the treatment of infectious complications as well as to assess the feasibility of allogeneic hematopoietic stem cell transplantation (HSCT) in this population. Aim: to analyze the specific aspects and safety of HSCT in children with mucormycosis. Materials and methods. This retrospective-prospective single-center study, conducted from 1 January 2013 to 31 March 2026 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation, included HSCT recipients with a pre-transplant diagnosis of mucormycosis. The diagnostic work-up included computed tomography, magnetic resonance imaging, ultrasound, endoscopy, bronchoalveolar lavage, and biopsy of various organs and tissues depending on the site of involvement. From these specimens, slides were prepared in clearing solution supplemented with calcofluor white, a fluorescent agent. The slides were then examined under a fluorescence microscope using short-wavelength excitation at 400× magnification.

Results

We analyzed treatment outcomes in 13 patients (median age: 11.7 years), 77% of whom had hematologic malignancies. At mucormycosis onset, pulmonary involvement was observed in 62% of the patients, paranasal sinus involvement in 54%; liver, spleen, and central nervous system involvement in 8%, and disseminated disease in 31%. Etiologic confirmation (77%) revealed Lichtheimia corymbifera (n = 2), Rhizomucor pusillus (n = 2), Rhizopus oryzae (n = 2), Rhizopus microsporus (n = 1), Mucor indicus (n = 1), and Mucor spp. (n = 2). All the patients received targeted antifungal therapy (amphotericin B, posaconazole, isavuconazole), with combination treatment used in 77% of cases. Surgical treatment was performed in 92% of the cases. Notably, radical resection significantly reduced the need for repeat surgeries (p = 0.02). Allogeneic HSCT was mostly performed using ex vivo αβ T-cell depletion (n = 11). At the time of transplantation, active infection was observed in 5 patients, partial response in 5 and complete response in 3. The median time to engraftment was 12 (10–35) days. Glucocorticoids for graft-versus-host disease were required in 3 patients. Mucormycosis was cured in 100% of cases. The median time to complete response was 82 days with early partial response (8 weeks) and 179 days with late response (p = 0.002). Infection status at HSCT did not affect the time to mucormycosis resolution. The overall survival was 59%, without any mucormycosis-associated deaths.

Conclusion

The use of modern HSCT technologies (such as αβ T-cell depletion) in combination with aggressive antifungal treatment enables successful transplantation even in children with active mucormycosis.

Zitieren

APA

Solopova, G. G., Shelikhova, L. N., Markova, Z. V., Shcherbakov, A. P., Voropaev, A. D., Suvorova, N. V., Maschan, A. A., & Novichkova, G. A. (2026). The feasibility and specific aspects of hematopoietic stem cell transplantation in children with pre-transplant invasive mucormycosis. Pediatric Hematology/Oncology and Immunopathology, 25(2), 96-106. https://doi.org/10.24287/j.1123

Vancouver

Solopova GG, Shelikhova LN, Markova ZV, Shcherbakov AP, Voropaev AD, Suvorova NV, et al. The feasibility and specific aspects of hematopoietic stem cell transplantation in children with pre-transplant invasive mucormycosis. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):96-106. doi:10.24287/j.1123

BibTeX
@article{Solopova2026,
  author = {Solopova, Galina G. and Shelikhova, L. N. and Markova, Zh. V. and Shcherbakov, A. P. and Voropaev, A. D. and Suvorova, N. V. and Maschan, A. A. and Novichkova, G. A.},
  title = {The feasibility and specific aspects of hematopoietic stem cell transplantation in children with pre-transplant invasive mucormycosis},
  journal = {Pediatric Hematology/Oncology and Immunopathology},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {96--106},
  doi = {10.24287/j.1123}
}
Kostenlos starten →